Literature DB >> 33169845

Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma.

Forat Lutfi1, Noa Holtzman2, Jonathan Siglin2, Ali Bukhari3, Moaath Mustafa Ali2, Dong Kim2, Gabriela Sanchez-Petitto4, David Gottlieb2, Kathleen Ruehle1, Elizabeth Hutnick1, Natalie Gahres1, Kim Hankey1, Seung Lee5, Mehmet Kocoglu1, Jean Yared6, Nancy Hardy7, Aaron Rapoport1, Saurabh Dahiya1.   

Abstract

Entities:  

Keywords:  CAR-T; GVHD; HSC TRANSPLANTATION; adoptive cellular therapy

Year:  2020        PMID： 33169845     DOI： 10.1111/bjh.17121

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  3 in total

Review 1.  Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.

Authors:  Pei-Hua Lu; Kai-Yan Liu; Xing-Yu Cao; Jing-Jing Li
Journal:  Int J Hematol       Date:  2022-06-23       Impact factor: 2.319

Review 2.  Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.

Authors:  Nikeshan Jeyakumar; Melody Smith
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

3.  CD19+ lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation.

Authors:  Isabel Martínez-Romera; Víctor Galán-Gómez; Berta González-Martínez; Pilar Guerra García; Sonsoles San Román Pacheco; Dolores Corral Sánchez; Yasmina Mozo Del Castillo; David Bueno Sánchez; Luisa Sisinni; Alba González Guerrero; Serafin Castellano Dámaso; Elena Sánchez Zapardiel; Beatriz Ruz Caracuel; Antonio Balas Pérez; Antonio Pérez-Martínez
Journal:  Front Immunol       Date:  2022-08-08       Impact factor: 8.786
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.